Biomedical subjects

C De Brabander

Publications and source records attributed to C De Brabander.

4 recordsLinked to original sources

PubMed2003

Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion.

Sustained release mini-matrices (multiple unit dosage form) were developed by means of hot-melt extrusion using ibuprofen as the model drug and ethyl cellulose as sustained release agent. Ibuprofen release from the ibuprofen-ethyl cellulose matrices (60:40 w/w) was too slow (20% in 24 h). Other excipientia (hydroxypropyl methylcellulose and xanthan gum) were added to the formulation to increase the drug release. Changing the viscosity and substitution type of HPMC, the amount of HPMC, the drug load and the HPMC:EC ratio modified the in vitro drug release. Burst release was noticed for the formulations containing HPMC and a nearly time independent drug release was seen for the xanthan gum based mini-matrices. Drug release from the mini-matrices was mainly diffusion controlled and swelling played an important role to obtain complete drug release. The formulations were at least 12 months stable during storage at 60% RH and room temperature. At a higher relative humidity and temperature the drug release increased.

Delayed-Action Preparations↗

PubMed2002

Characterization of ibuprofen as a nontraditional plasticizer of ethyl cellulose.

This study describes the characterization of the plasticizing properties of ibuprofen (IBP) on hot-melt extruded ethyl cellulose (EC). The thermal behavior of hot-melt extrudates containing 0, 5, 10, and 20% (w/w) IBP was evaluated using modulated temperature differential scanning calorimetry. By means of comparison, co-evaporates containing the same concentrations of IBP and EC, were also evaluated. Both methods yielded solid solutions having one glass transition temperature indicating compatibility between drug and polymer. A similar decrease in glass transition temperature was noticed with increasing IBP concentration in the solid solutions prepared via both methods, indicating its plasticizing effect. The plasticizing efficiency was of the same magnitude as for the traditionally used plasticizers. Infrared spectroscopy was performed for better understanding of the chemical interactions in the molecular dispersions and confirmed the existence of hydrogen bonds between IBP and EC. Overall, the study has highlighted the plasticizing properties of IBP on EC during hot-melt extrusion.

Cellulose↗

PubMed2000

Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax.

The bioavailability of ibuprofen from matrix mini-tablets based on microcrystalline wax and a starch derivative was tested. An oral dose of 300 mg of ibuprofen was administered to healthy volunteers (n=8) in a randomized cross-over study design either as a commercial matrix formulation (Ibu-Slow 600) or as mini-tablets (filled into hard gelatin capsules). The mini-tablets consisted of 60% ibuprofen, 15% Paracera M (wax), 22.5% DDWM (starch) and 2.5% triacetin (lubricant). t50% of the in vitro release was 4.5 and 5 h for the mini-tablet and Ibu-slow formulations, respectively. Both formulations behaved in vivo as sustained-release formulation; their HVDt50%Cmax value was determined at 5.6 and 5.1 h for the mini-tablet and Ibu-slow formulations, respectively. A significantly higher value of Cmax was seen for the mini-tablet formulation, resulting in a relative bioavailability of 116 +/- 22.6% compared to the Ibu-slow matrix. These data demonstrate that the experimental mini-tablets can be used to formulate sustained-release dosage forms.

Adult↗

PubMed2000

Matrix mini-tablets based on starch/microcrystalline wax mixtures.

Matrix mini-tablets based on a combination of microcrystalline waxes and starch derivatives were prepared using ibuprofen as a model drug. The production of mini-tablets was preferred over the production of pellets, as up-scaling of the pelletisation process seemed problematic. Prior to tabletting, melt granulation in a hot stage screw extruder and milling were required. The in vitro drug release was varied using microcrystalline waxes with a different melting range, the slowest drug release being obtained with a formulation containing a microcrystalline wax with a melting range between 68 and 72 degrees C. Generally speaking increasing the wax concentration resulted in a slower drug release. In vitro drug release profiles were also modified using different starches and mixtures of starches. Increasing the ibuprofen concentration to 70% resulted in a faster drug release rate.

Capsules↗